Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) target, is showing promising outcomes in initial patient trials . Ongoing inquiry indicates https://digibookmarks.com/story21312802/retatrutide-emerging-investigations-and-potential-clinical-uses